Navigation Links
Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
Date:4/28/2010

SAN FRANCISCO, April 28 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer biotherapeutics company, today expanded its board of directors with the appointment of Paul B. Cleveland, executive vice president of corporate development and chief financial officer of Affymax, Inc.  

"With JX-594 entering Phase 3 trials for the treatment of liver cancer by the end of this year and a strong pipeline of novel clinical-stage products behind it, we believe Paul's superior financial acumen and strategic business insight will add important perspective to our board as we evaluate financing and partnering opportunities for optimal growth on our path to commercialization," said David H. Kirn, M.D., president and chief executive officer of Jennerex.

Mr. Cleveland brings over 20 years of experience in strategic corporate transactions and investment banking to the Jennerex board. As executive vice president of corporate development and chief financial officer for Affymax, he manages all business development, strategic planning, financial and legal activities. Prior to Affymax, he served as managing director of the investment banks Integrated Finance, Ltd. and J.P. Morgan Chase and Co. (formerly Hambrecht & Quist), leading healthcare and technology mergers and acquisitions for the firms. Prior to his tenure in investment banking, he was a partner at Cooley Godward LLP. Mr. Cleveland serves as a member of the board of directors of Sangamo BioSciences, Inc.  He holds a J.D. from Northwestern University School of Law and an A.B. from Washington University in St. Louis.

"Paul will be an excellent complement to Jennerex's board of directors, and we welcome him to our team.  His depth of experience will add significant value as we make strategic business decisions going forward," stated Brennan Mulcahy, chairman of the board of Jennerex.

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com .


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
2. Jennerex Closes $5 Million First Tranche of Series C Financing
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
5. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
6. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
7. Biotech Industry Showing Resilience Despite Challenging Conditions
8. Global Jatrophaworld Training 2010... Set to Create and Build a Sustainable Biodiesel Industry
9. HealthTalker Adds Industry Expert Collie Turner to Its Executive Team
10. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
11. HealthTalker Programs Leveraging the Power of Word of Mouth Find Huge Success for Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... ... “The American Academy of Anti-Aging and Preventative Medicine declares War on Dementia,” ... will Die with a form of Dementia. , The 28,000 Physicians and Scientists ... the potential to slow and reverse Dementia and brain aging. , If you think ...
(Date:9/25/2017)... ... 2017 , ... Cambridge Semantics , a big data ... the Big Data special edition of CIOReview magazine. , Since 2013, CIOReview ... technologies and solutions that are advancing the industry and optimizing businesses. A distinguished ...
(Date:9/25/2017)... UT, and Portland, OR (PRWEB) , ... ... ... CallTower , an industry-leading Unified Communications (UC) and Collaboration company, and ... in real-time, announced today a strategic alliance to extend CallTower’s Unified Communication ...
(Date:9/22/2017)... ... September 22, 2017 , ... HOLLOWAY AMERICA, ... booth at premier packaging event PACK EXPO International in Las Vegas from September ... Institute (PMMI). , At this year’s PACK EXPO at the Last Vegas Convention ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
Breaking Biology News(10 mins):